Skip to main content

Table 2 Baseline clinical details of participants

From: Escitalopram in the prevention of posttraumatic stress disorder: a pilot randomized controlled trial

Total sample (N = 29)

Escitalopram (N = 12)

Placebo (N = 17)

Significance

ASD

   

Full: 27

N = 12

N = 15

 

Partial: 2

N = 0

N = 2

p = 0.39

Any MINI disorder

   

Yes: 19

N = 7

N = 12

 

No: 10

N = 5

N = 5

p = 0.50

CAPS PTSD

   

Yes: 15

N = 4

N = 11

 

No: 14

N = 8

N = 6

p = 0.09

CAPS (mean ± SD)

   

55.10 ± 23.50

45.33 ± 21.43

62.00 ± 22.98

p = 0.06

CGI-S (mean ± SD)

   

3.24 ± 0.87

3.08 ± 0.10

3.35 ± 0.79

p = 0.35

MADRS (mean ± SD)

   

14.79 ± 9.56

11.92 ± 9.42

16.82 ± 9.40

p = 0.05

VAS-D (mean ± SD)

   

4.45 ± 2.65

3.75 ± 2.60

4.94 ± 2.66

p = 0.24

VAS-A (mean ± SD)

   

5.22 ± 2.16

5.33 ± 2.19

5.15 ± 2.21

p = 0.82

SDS (mean ± SD)

   

12.10 ± 7.65

8.83 ± 6.46

14.41 ± 7.75

p = 0.05

  1. CAPS: Clinician Administered PTSD Scale; CGI-S: Clinical Global Impressions Scale- severity; MADRS: MINI: MINI International Neuropsychiatric Interview; Montgomery Asberg Depression Rating Scale; SD: standard deviation; SDS: Sheehan Disability Scale; VAS-D: Visual Analogue Scale-Depression; VAS-A: Visual Analogue Scale- Anxiety.
  2. Note: numbers may not add up to 100% due to missing data.